Recent Updates
Recently added Catalysts

BGB-16673

Phase 3

Chronic Lymphocytic Leukemia | Small molecule | Oncology |BeOne Medicines Ltd.|Last Updated: Sep 9, 2026

Target and mechanism

Molecular targetBTK
Target classKinase
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment153

FDA Designations

No designations recorded

Clinical trial landscape

BGB-16673 · 5 trials · 13 indications

Phase 3 1Phase 1 4
NCT06970743A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsChronic Lymphocytic Leukemia
ACTIVE NOT_RECRUITING153 Analytics
PHASE3ACTIVE NOT_RECRUITING
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Chronic Lymphocytic LeukemiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Progression-Free Survival (PFS) by IRC
Approximately 23 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with R/R CLL and the Lugano Classification for patients with R/R SLL.

Part A: Number of participants with adverse events (AEs)
Up to approximately 4 months

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including findings from laboratory tests and electrocardiogram results.

Part B: Number of participants with adverse events (AEs)
Up to approximately 6 weeks

Number of participants with TEAEs and SAEs, including findings from laboratory tests and electrocardiogram results.

Part A: Maximum observed plasma concentration (Cmax) of tacabrutideg
Up to approximately 10 weeks
Part A: Minimum observed plasma concentration (Cmin) of tacabrutideg
Up to approximately 10 weeks
Part A: Time to reach maximum observed plasma concentration (Tmax) of tacabrutideg
Up to approximately 10 weeks
Part A: Apparent terminal elimination half life (t1/2) of tacabrutideg
Up to approximately 10 weeks
Part A: Area under the curve (AUC) of tacabrutideg
Up to approximately 10 weeks
Part A: Apparent oral clearance (CL/F) of tacabrutideg
Up to approximately 10 weeks
Part A: Apparent volume of distribution (Vz/F) of tacabrutideg
Up to approximately 10 weeks
Part A: Accumulation Ratio of AUC for tacabrutideg
Up to approximately 10 weeks
Part A: Accumulation Ratio of Cmax for tacabrutideg
Up to approximately 10 weeks
Part A and Part B: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) of BGB-16673
Part A: Day 1 and Day 20; Part B: Day 1 and Day 17
Part A and Part B: Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) of BGB-16673
Part A: Day 1 and Day 20; Part B: Day 1 and Day 17
Part A and Part B: Maximum Observed Concentration (Cmax) of BGB-16673
Part A: Day 1 and Day 20; Part B: Day 1 and Day 17
Total Radioactivity Recovery (fet1-t2) in Urine and Feces
Approximately 35 Days
Area Under the Plasma Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) of BGB-16673
Approximately 35 Days
Area Under the Plasma Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) for Total Radioactivity in Plasma and Whole Blood
Approximately 35 Days
Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) of BGB-16673
Approximately 35 Days
Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) for Total Radioactivity in Plasma and Whole Blood
Approximately 35 Days
Maximum Observed Plasma Concentration (Cmax) of BGB-16673
Approximately 35 Days
Maximum Observed Plasma Concentration (Cmax) for Total Radioactivity in Plasma and Whole Blood
Approximately 35 Days
Time of the Maximum Observed Plasma Concentration (Tmax) of BGB-16673
Approximately 35 Days
Time of the Maximum Observed Plasma Concentration (Tmax) for Total Radioactivity in Plasma and Whole Blood
Approximately 35 Days
Apparent Terminal Elimination Half-life (t1/2) of BGB-16673
Approximately 35 Days
Apparent Terminal Elimination Half-life (t1/2) for Total Radioactivity in Plasma and Whole Blood
Approximately 35 Days
Urinary recovery of BGB-16673 (fet1-t2)
Approximately 35 Days
Quantitative metabolic profiles of BGB-16673 in plasma and excreta
Approximately 35 Days
Identification of BGB-16673 major metabolites in plasma and excreta
Approximately 35 Days
Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
From first dose of the study drug(s) to 30 days after the last dose or before initiation of a new anticancer therapy, whichever occurs first (up to approximately 3 years)

Number of participants with AEs and SAEs as graded by the National Cancer Institute- Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE 5.0), including AEs that meet protocol-defined dose-limiting toxicity (DLT) criteria.

Phase 1: Recommended Phase 2 dose (RP2D) of BGB-16673
From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)

As determined by the sponsor based on the Safety Monitoring Committee's recommendation considering totality of the available clinical safety, clinical efficacy, pharmacokinetics, and pharmacodynamics data.

Phase 1a: Maximum tolerated dose (MTD) of BGB-16673
From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)

The highest dose evaluated as recommended by the Bayesian Optimal Interval Design with Informative Prior (iBOIN) design or the maximum assessed dose (MAD).

Phase 2: Overall Response Rate (ORR) in participants with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Up to approximately 3 years

ORR is defined as the percentage of participants with partial response or better according to the Independent Review Committee (IRC) assessment and as determined by Lugano criteria.

Phase 2: ORR in participants with R/R Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Up to approximately 3 years

ORR is defined as the percentage of participants with partial response or better as assessed by the IRC and determined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for CLL and by Lugano criteria for SLL

Secondary Endpoints

PFS as Assessed by the Investigator
Approximately 12 Months
Overall Survival (OS)
Approximately 21 Months
Overall Response Rate (ORR) by IRC and Investigator Assessment
Approximately 23 Months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A: BGB-16673 MonotherapyEXPERIMENTALParticipants will receive BGB-16673 once daily until any of the treatment discontinuation criteria are met
Arm B: Investigator's ChoiceACTIVE_COMPARATORParticipants will receive investigator's choice of bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab for up to six 28-day cycles. Participants with unequivocal disease progression confirmed by Independent Review Committee (IRC) may cross over to receive treatment with BGB-16673 at the Investigator's discretion
Part A (CSU): TacabrutidegEXPERIMENTALSequential cohorts of increasing dose levels of tacabrutideg will be evaluated in participants with CSU.
Part A (CSU): PlaceboPLACEBO_COMPARATORParticipants with CSU will receive matching placebo orally for 28 days and then crossover to receive tacabrutideg.
Part B (Healthy Participants): TacabrutidegEXPERIMENTALSequential cohorts of increasing dose levels of tacabrutideg will be evaluated in healthy participants.
Part A: BGB-16673 + Phenytoin (CYP3A Inducer)EXPERIMENTALParticipants will receive multiple doses of Phenytoin to determine its effect on BGB-16673
Part B: BGB-16673 + Itraconazole (CYP3A Inhibitor)EXPERIMENTALParticipants will receive multiple doses of Itraconazole to determine its effect on BGB-16673
Single Arm: [14C]-BGB-16673EXPERIMENTALParticipants will receive a single dose of \[14C\]-BGB-16673
Phase 1a Monotherapy Dose EscalationEXPERIMENTALBGB-16673 will be orally administered.
Phase 1b Monotherapy Safety ExpansionEXPERIMENTALBGB-16673 will be orally administered.
Phase 2 Monotherapy Dose ExpansionEXPERIMENTALBGB-16673 will be administered at the recommended Phase 2 dose (RP2D) that was identified in Part 1.

Interventions

NameTypeDescription
BGB-16673DRUGAdministered orally
BendamustineDRUGAdministered intravenously
RituximabDRUGAdministered intravenously
MethylprednisoloneDRUGAdministered intravenously
ChlorambucilDRUGAdministered orally
ObinutuzumabDRUGAdministered intravenously
TacabrutidegDRUGAdministered orally
PlaceboDRUGAdministered orally
ItraconazoleDRUGAdministered orally
PhenytoinDRUGAdministered orally
[14C]-BGB-16673DRUGAdministered orally as suspension in lipid vehicle
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites56

Inclusion Criteria: 1. Confirmed diagnosis of CLL/SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria. 2. Previously received treatment for CLL/SLL with a covalent BTKi. 3. Measurable disease by computer tomography/magnetic resonance imagi...

Countries:ChinaTaiwanUnited States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMSep 9, 2026NCT07005713Status: ACTIVE_NOT_RECRUITING → RECRUITING
MEDIUMSep 9, 2026NCT07005713Status: ACTIVE_NOT_RECRUITING → RECRUITING
LOWAug 24, 2026NCT06970743lastUpdatePostDate: changed
LOWAug 24, 2026NCT06970743lastUpdatePostDate: changed
LOWAug 11, 2026NCT06970743lastUpdatePostDate: changed
LOWAug 11, 2026NCT06970743lastUpdatePostDate: changed
LOWAug 11, 2026NCT06970743lastUpdatePostDate: changed
MEDIUMJul 24, 2026NCT06970743enrollmentType: changed
MEDIUMJul 24, 2026NCT06970743enrollmentType: changed
MEDIUMJun 29, 2026NCT06970743Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJun 29, 2026NCT06970743Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWJun 22, 2026NCT06970743lastUpdatePostDate: changed
LOWJun 22, 2026NCT06970743lastUpdatePostDate: changed

Frequently asked questions about BGB-16673

What is BGB-16673 used for?

BGB-16673 is an investigational small molecule being studied for B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, and Richter's transformation, as well as for chronic spontaneous urticaria. It is also being evaluated in healthy volunteers for pharmacokinetic studies. The drug is in Phase 1 clinical development.

What does BGB-16673 target?

BGB-16673 targets Bruton tyrosine kinase (BTK), a kinase involved in B-cell signaling. It is designed as a BTK-targeted protein degrader, meaning it works by degrading the BTK protein rather than simply inhibiting its activity. This mechanism is being studied in B-cell malignancies and chronic spontaneous urticaria.

Who is developing BGB-16673?

BGB-16673 is being developed by BeOne Medicines Ltd., a biopharmaceutical company listed under the ticker ONC. The company is conducting Phase 1 clinical trials of this investigational small molecule across multiple indications, including oncology and immunology.

What phase is BGB-16673 in?

BGB-16673 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 program includes trials in patients with B-cell malignancies, healthy volunteers for drug metabolism studies, and adults with chronic spontaneous urticaria.

What clinical trials is BGB-16673 in?

BGB-16673 is being studied in four Phase 1 trials. NCT05294731 is recruiting patients with B-cell malignancies in China. NCT06776679 and NCT06906809, both completed, examined drug absorption and metabolism in healthy volunteers in the United States. NCT07005713 is evaluating multiple ascending doses in chronic spontaneous urticaria.

Is BGB-16673 being studied in chronic spontaneous urticaria?

Yes, BGB-16673 is being studied in chronic spontaneous urticaria. Trial NCT07005713 is a Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of BGB-16673 in adults with this condition. The trial is active but not recruiting, with an enrollment of 34 participants in China.